Investigation of the clinical, serological and genetic factors that determine primary non-response, loss of response and adverse drug reactions to Anti-TNF drugs in patients with active luminal Crohn's Disease - EXTENSION
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PANTS-E
- Sponsors AbbVie; Merck Sharp & Dohme
- 23 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 24 Oct 2015 Accrual to date is 19% according to United Kingdom Clinical Research Network record.
- 11 Oct 2015 Accrual to date is 14% according to United Kingdom Clinical Research Network record.